[	0	0
The	1	3
effect	5	10
of	12	13
omeprazole	15	24
on	26	27
healing	29	35
of	37	38
duodenal	40	47
ulcers	49	54
,	55	55
Helicobacter	57	68
pylori	70	75
and	77	79
gastritis	81	89
]	90	90
.	91	91

Losec	93	97
(	99	99
omeprazole	100	109
)	110	110
Astra	112	116
Co	118	119
.	120	120
is	122	123
a	125	125
blocker	127	133
of	135	136
the	138	140
proton	142	147
pump	149	152
of	154	155
the	157	159
parietal	161	168
cell	170	173
.	174	174

It	176	177
inhibits	179	186
basal	188	192
and	194	196
stimulated	198	207
HCl	209	211
secretion	213	221
.	222	222

It	224	225
is	227	228
used	230	233
for	235	237
treatment	239	247
of	249	250
gastroduodenal	252	265
ulcers	267	272
,	273	273
reflux	275	280
oesophagitis	282	293
and	295	297
Zollinger	299	307
Ellison	309	315
'	316	316
s	317	317
syndrome	319	326
.	327	327

In	329	330
a	332	332
group	334	338
of	340	341
17	343	344
patients	346	353
with	355	358
duodenal	360	367
ulcers	369	374
the	376	378
authors	380	386
investigated	388	399
the	401	403
effect	405	410
of	412	413
omeprazole	415	424
on	426	427
(	429	429
1	430	430
)	431	431
healing	433	439
of	441	442
duodenal	444	451
ulcers	453	458
and	460	462
bulbitis	464	471
after	473	477
2	479	479
-	480	480
4	481	481
weeks	483	487
of	489	490
therapy	492	498
,	499	499
(	501	501
2	502	502
)	503	503
elimination	505	515
of	517	518
Helicobacter	520	531
pylori	533	538
in	540	541
the	543	545
antrum	547	552
,	553	553
(	555	555
3	556	556
)	557	557
chronic	559	565
antral	567	572
gastritis	574	582
.	583	583

Ad	585	586
1	588	588
.	589	589

After	591	595
two	597	599
weeks	601	605
of	607	608
treatment	610	618
the	620	622
authors	624	630
found	632	636
that	638	641
5	643	643
of	645	646
17	648	649
chronic	651	657
duodenal	659	666
ulcers	668	673
were	675	678
healed	680	685
in	687	688
the	690	692
remainder	694	702
substantial	704	714
regression	716	725
was	727	729
found	731	735
.	736	736

Four	738	741
-	742	742
week	743	746
treatment	748	756
led	758	760
to	762	763
healing	765	771
of	773	774
16	776	777
from	779	782
a	784	784
total	786	790
of	792	793
17	795	796
ulcers	798	803
(	805	805
P	806	806
<	808	808
0	810	810
.	811	811
001	812	814
)	815	815
,	816	816
i	818	818
.	819	819
e	821	821
.	822	822
94	824	825
%	826	826
.	827	827

In	829	830
subjects	832	839
with	841	844
ulcers	846	851
and	853	855
bulbitis	857	864
(	866	866
12	867	868
patients	870	877
)	878	878
the	880	882
ulcer	884	888
healed	890	895
in	897	898
11	900	901
instances	903	911
,	912	912
in	914	915
7	917	917
patients	919	926
residual	928	935
bulbitis	937	944
persisted	946	954
.	955	955

Ad	957	958
2	960	960
.	961	961

H	963	963
.	964	964
pylori	966	971
was	973	975
detected	977	984
before	986	991
treatment	993	1001
in	1003	1004
16	1006	1007
of	1009	1010
17	1012	1013
patients	1015	1022
,	1023	1023
after	1025	1029
treatment	1031	1039
only	1041	1044
in	1046	1047
5	1049	1049
(	1051	1051
P	1052	1052
<	1054	1054
0	1056	1056
.	1057	1057
001	1058	1060
)	1061	1061
.	1062	1062

Ad	1064	1065
3	1067	1067
.	1068	1068

Chronic	1070	1076
gastritis	1078	1086
was	1088	1090
recorded	1092	1099
before	1101	1106
treatment	1108	1116
in	1118	1119
all	1121	1123
patients	1125	1132
.	1133	1133

Treatment	1135	1143
reduced	1145	1151
its	1153	1155
activity	1157	1164
and	1166	1168
the	1170	1172
presence	1174	1181
of	1183	1184
H	1186	1186
.	1187	1187
pylori	1189	1194
.	1195	1195
